On December 8, 2022, Hangzhou 1gene Technology Co., Ltd. closed the transaction. The company has received CNY 1,94,81,560 ($2,800,000) in its Series B round of funding led by new investor, ChengDa Pharmaceuticals Co., Ltd.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
18.22 CNY | -2.62% | +2.19% | -28.35% |
1st Jan change | Capi. | |
---|---|---|
-28.35% | 381M | |
+63.05% | 856B | |
+39.42% | 631B | |
-4.78% | 359B | |
+17.52% | 325B | |
+8.43% | 297B | |
+14.19% | 244B | |
+5.81% | 234B | |
+16.77% | 226B | |
+14.63% | 177B |
- Stock Market
- Equities
- 301201 Stock
- News ChengDa Pharmaceuticals Co., Ltd.
- Hangzhou 1gene Technology Co., Ltd. announced that it has received CNY 19.48156 million in funding from ChengDa Pharmaceuticals Co., Ltd.